Britannia Life Sciences Inc.
BLSIF
$0.06
$0.03100.00%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -- | -- | 40.21% | -107.57% | 6,841.51% |
| Total Depreciation and Amortization | -- | -- | 1.77% | 5.61% | -1.83% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -- | -309.29% | 100.51% | -2,559.46% |
| Change in Net Operating Assets | -- | -- | 100.59% | -396.50% | -46.39% |
| Cash from Operations | -- | -- | 54.08% | 65.57% | -555.47% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -1,908.97% | -102.45% | 10,120.90% |
| Cash from Investing | -- | -- | -1,908.97% | -102.45% | 10,120.90% |
| Total Debt Issued | -- | -- | -- | -- | 2,036.57% |
| Total Debt Repaid | -- | -- | -1.68% | 97.12% | -4,438.16% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 66.25% |
| Cash from Financing | -- | -- | -1.85% | 88.18% | 59.00% |
| Foreign Exchange rate Adjustments | -- | -- | 179.07% | 56.12% | -790.91% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -- | -288.37% | -121.72% | 50,738.30% |